3rd World Conference on Luteinizing Hormone in ART
Applying technologies
learning from nature
Held on 27-28 May . Naples
Free On-demand and E-learning materials


The role of luteinizing hormone (LH) during folliculogenesis has intrigued the scientific and medical community for at least three decades. There is an emerging galaxy of research to explore concerning this enigmatic subject. The availability of recombinant drugs now offers, for the first time, the opportunity to examine the role of follicle stimulating hormone and LH separately. An emerging topic during last year’s conference was LH supplementation to improve the outcome in a subgroup of low prognosis patients selected according to POSEIDON classification

During this conference we will discuss the management of these low prognosis patients in greater detail. Notably, we will move beyond controlled ovarian stimulation to explore further the involvement of LH in personalizing the luteal phase and in male infertility. Also, on the agenda will be the extra-gonadal effect of LH, including potential immune-modulation at the endometrium.

Following the precedent set at last year’s conference, considerable time will be devoted to basic science, alongside such controversial issues as progesterone rise and pharmacogenomics. This year we have attracted prominent scientists from the worlds of endocrinology, andrology, immunology and embryology to take part in our engaging educational programme.

Learning Objectives

Target Audience

This programme is designed for clinicians and biologists working in assisted reproductive medicine, who want to acquire up-to date information to improve their current practice.


The accreditation is valid for the live event onsite as well as for the recorded live streaming for a period of 3 months after the conference.

The Third World Conference on Luteinizing Hormone in ART, Naples, Italy, 27/05/2022-28/05/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 8 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

The content of the following has been certified by the CPD Certification Service as conforming to continuing professional development principles, 3rd World Conference on Luteinizing Hormone in ART: Applying technologies, learning from nature. Event: 27th –28th May 2022

Free Educational resources

Enter our new E-Learning platform to access the educational materials.

You will be able to review the conference materials as well as watch the recorded streaming and get your CME certificate.

#LH2022 Gallery

3rd World Conference on Luteinizing Hormone in ART

Applying technologies,

learning from nature

Held on 27-28 May . Naples, Italy Free On-demand and E learning materials

Final Program

Download the PDF preliminary programme


The 3rd World Conference has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 8 European CME credits (ECMEC®s).


The official language of this live educational conference will be English.


Carlo Alviggi

Naples, Italy

Robert Fisher

Hamburg, Germany

Sandro Esteves

Campinas, Brazil

Peter Humaidan

Aarhus, Denmark


Federico II University
Naples, Italy

University of Saskatchewan
Saskatoon, Canada

Valencia, Spain

Centre for Gynaecological Endocrinology and Reproductive Medicine
Stuttgart, Germany

University of Modena and Reggio Emilia
Modena, Italy

Federico II University
Naples, Italy

Federico II University
Naples, Italy

Androfert – Andrology and Human Reproduction Clinic
Campinas, Brazil

Fertility Centre Hamburg
Hamburg, Germany

Fertility Clinic, Skive Regional Hospital
Faculty of Health, Aarhus University
Aarhus, Denmark

Saint Camillus International University Of Health Science
Rome, Italy

Department of Medical and Surgical Sciences for Children and Adults

Institute of Obstetrics and Gynecology Policlinico di Modena

University of Modena and Reggio Emilia

Modena, Italy

Federico II University
Naples, Italy

Tel-Aviv University
Tel-Aviv, Israel

Dexeus University Hospital

Barcelona, Spain

University of Ferrara

Ferrara, Italy

MATER PRIME – Reproductive Medicine
São Paulo, Brazil

University of Modena and Reggio Emilia
Modena, Italy

King’s College London

London, UK

GeneraLife, Centres for Reproductive Medicine

Rome, Italy


Universidad Rey Juan Carlos

Madrid, Spain

Anatolia IVF and Women’s Health Center

Ankara, Turkey

Final Program

General Information


This program is designed in partnership with:

CME Provider

Med.E.A – Medical Education Academy



Our educational activities are supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany; and additional support from FUJIFILM EUROPE GMBH, Fujifilm Italia S.p.A., FUJIFILM France S.A.S and S&R Farmaceutici Spa.

· Carlo Alviggi ·

Carlo Alviggi earned his MD degree in 1994, from the Faculty of Medicine of the University of Naples “Federico II” in Naples, Italy; he specialized in obstetrics and gynaecology in 1998, and gained a PhD in 2001, from the same university. During his career, he collaborated with: The Imperial College of London, in London, UK; the Laboratory of Immunology of the Italian National Research Council in Naples; and the Autoimmunity and Tolerance Laboratory of the University of California in Los Angeles, CA, USA. This network resulted in various publications, some of which concern new hypotheses on the pathogenesis of pelvic endometriosis. He is now an associate professor in reproductive medicine at the Fertility Unit of the University of Naples “Federico II”. Professor Alviggi’s current research interests are the role of luteinizing hormone (LH) in folliculogenesis; the use of LH-containing drugs in patients undergoing ovarian controlled stimulation for IVF; the pathogenesis of pelvic endometriosis; oncofertility; reproductive endicrinology and the genetics of human reproduction. He has participated in several national and international (phase 2 and 3) multicentric, prospective randomized trials. Professor Alviggi has published extensively and has been invited to lecture at over 200 international meetings dealing with reproductive medicine and gynaecological endocrinology; he is also starter and co-founder of the Poseidon group, an international collaborative network dedicated to low prognosis patients in Assisted Reproductive Technology and vice-President of the “Società Italiana di Fertilità e Sterilità – Medicina della Riproduzione”.

· Robert Fischer ·

Robert Fischer is the founder and Medical Director of the Fertility Center Hamburg (FCH) in Hamburg, Germany. Dr Fischer trained in obstetrics and gynaecology at the University Hospital of Münster, Germany, from 1979 to 1982 and at the Queen’s Medical Centre, University of Nottingham, UK. In 1983, Dr Fischer pioneered the first German outpatient IVF unit in Hamburg and became its Medical Director. The unit moved to a new location in 1998, and its name was changed to the “Fertility Center Hamburg”.

In July 1998, the Fertility Center Hamburg was one of the first centres, both in Germany and worldwide, to introduce quality management, and it was certified according to the ISO 9001 and accredited for IVF laboratories (ISO 17025). Dr Fischer’s main research interests are in the development of stimulation protocols, luteinizing hormone supplementation, and gonadotropin-releasing hormone agonist triggering, as well as further development of quality management systems in IVF centres. He is a founding member of the European Society of Human Reproduction and Embryology (ESHRE); a founding member of the POSEIDON (Patient Oriented Strategies Encompassing IndividualizeD Oocyte Number) group);  Member of the  Scientific Committee of Excellence in Medical Education (EXCEMED- formerly the Serono Symposia International Foundation) and Scientific director of  Med.E.A.( Medical Education Academy)

· Sandro C. Esteves ·

Sandro Esteves, MD., Ph.D. is a board-certified urologist and consultant in assisted reproduction with over 25 years of clinical experience in all areas of reproductive medicine, with specialization in male reproduction.

He is listed by Expertscape among the top three world experts in the areas of male infertility, azoospermia, varicocele, and sperm retrieval techniques. Sandro has been also included in the list of the world’s most influential scientists.

He is the Founder and Medical Director of the ANDROFERT Andrology & Human Reproduction Clinic, in Campinas, Brazil. Dr. Esteves established the first Brazilian Fertility Clinic with a primary focus on male infertility, as well as the very first to introduce quality management as per the ISO 9001 standards and IVF cleanroom technology (ISO 14644-1).

Sandro is also a Collaborating Professor of Urology at the University of Campinas (UNICAMP, Brazil) and Honorary Professor of Reproductive Medicine at Aarhus University (Denmark). Dr. Esteves received his Master’s in Surgery from the University of Campinas Medical School and his Ph.D. in Urology from the Federal University of São Paulo Medical School. His post-doctoral training was at the American Center for Reproductive Medicine at the Cleveland Clinic in the United States. He has received many research grants and awards from national and international societies.

Prof. Esteves is the author of 10 textbooks in the fields of infertility and reproductive medicine. He was also the co-editor of several Journal Supplements and has published over 400 hundred scientific papers in journals like Lancet, Nature, Human Reproduction Update, Human Reproduction, Fertility and Sterility, etc. His current Hirsch index (h-index) is 63 while his citation count is over 12K. He is a member of ‘Faculty Opinions’ in the area of reproductive endocrinology & infertility. Dr. Esteves is Associate Editor of Frontiers in Endocrinology (Reproduction), Andrology, International Brazilian Journal of Urology, Regional Editor of the Société Internationale d’Urologie Journal, an editorial board member of Nature Reviews Urology, and a dozen of other peer-reviewed scientific journals. He is also a co-founder of the POSEIDON group and currently serves as a Chair of the Male Infertility Section of the WHO Infertility Guidelines Development Group.

Dr. Esteves is a very much requested speaker and presents over 50 lectures annually. He also regularly conducts infertility workshops, provides consulting services in the area of quality management for ART Clinics,

· Peter Humaidan ·

Professor Peter Humaidan is a specialist in reproductive endocrinology, professor at The Fertility Clinic Skive Regional Hospital, Aarhus University, Denmark and Honorary professor at Odense University, Denmark. During his scientific work he has primarily focused on developing individualized treatment protocols for the infertile patient. His doctoral thesis (DMSc) explored the role of LH during the follicular and luteal phases in controlled ovarian stimulation. His main fields of interest are triggering of ovulation with GnRH agonist, role of LH during the follicular and luteal phases, role of the female genital tract microbiota for reproductive outcomes, OHSS prevention, and role of sperm DNA fragmentation for spontaneous and assisted reproduction. He is the founder of the international society “The Copenhagen GnRHa Triggering Workshop Group” who introduced the GnRHa trigger in modern IVF, changing trigger policies worldwide. Moreover, he is co-founder of the POSEIDON group which suggested a new stratification of the poor responder patient, and a past board member of the ESHRE SIG Endocrinology Group. He is in the Elsevier, Stanford global list of 2% top scientists, and he authored and co-authored 250 + articles (H-index 67, Google Scholar) in international peer reviewed journals as well as chapters in textbooks and the Danish guidelines for OHSS prevention. Peter Humaidan has a wide international scientific network and is frequently invited as a speaker at international conferences.